In France, 12-17 year olds can already receive the Comirnaty vaccine from Pfizer / BioNTech or Spikevax from Moderna, authorized for adolescents since June 15.
But no decision has yet been made regarding the under-12s.
And for good reason, the results of the two main pediatric clinical trials in progress have not yet been sent to the European Medicines Agency (EMA), responsible for evaluating the marketing authorization applications (MA) of vaccines against Covid for the entire European Union.
To discover
Covid-19: the third vaccine dose, instructions for use
Read also
Vaccination of children: the reluctant French
The Pfizer / BioNTech trial, launched in June, which will include up to 4,500 patients aged 6 months to 11 years, in the United States, Finland, Spain and Poland, and that of Moderna ( more than 12,000 participants).
Pfizer's results for the 5-11 age group should be sent to the Food and Drug Administration in September-October for possible emergency marketing authorization. end of
This article is for subscribers only.
You have 81% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in